Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Results available

MGA031, Sirolimus and Tacrolimus in Islet Transplantation

NCT00265473
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans, Everolimus, anti-thymocyte globulin, Cyclosporine
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
No Longer Available No phase listed Expanded access

Islet Transplant for Type 1 or Surgical Diabetes

NCT01606475
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
Interventions
Allogeneic islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Active, not recruiting Phase 1Phase 2 Interventional

Allogenic Islet Cell Transplantation

NCT00160732
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 58 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Active, not recruiting Phase 2 Interventional

Islet Cell Transplant for Type 1 Diabetes

NCT01909245
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Diabetes Mellitus, Type I
Interventions
islets
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Miami, Florida
Terminated Phase 1Phase 2 Interventional Results available

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus, anti-thymocyte globulin
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Terminated Phase 1Phase 2 Interventional Results available

Islet Transplantation for Type 1 Diabetes Mellitus

NCT00437398
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet Transplant
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota